ABSTRACT
Traditionally, the treatment of intracerebral hemorrhage (ICH) has been largely empirical. However, this situation is rapidly changing due to the accumulation of data from rigorously conducted, randomized clinical trials that address old treatment quandaries and assess novel and promising therapeutic modalities. Evidence provided by these trials is likely to generate new standards of care for the management of patients with ICH.
